3D Bioprinted retina models for drug screening
用于药物筛选的 3D 生物打印视网膜模型
基本信息
- 批准号:10916043
- 负责人:
- 金额:$ 226.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalBlood-Retinal BarrierBruch&aposs basal membrane structureChoroidChoroidal NeovascularizationDiseaseDrug ModelingsDrug ScreeningEngineeringExtracellular MatrixGoalsHumanPathologic NeovascularizationPhotoreceptorsPreventionRecoveryRecurrenceRetinaRetinal DiseasesStructure of retinal pigment epitheliumTechniquesTherapeuticTissue ModelTissuesVascular EndotheliumVascularizationVirus DiseasesVisionZIKV infectionangiogenesisbevacizumabbioprintingclinically relevanthypoxia inducible factor 1improvedin vitro Modelinduced pluripotent stem cellnew therapeutic targettherapeutic developmenttherapeutic target
项目摘要
An engineered ocular tissue of outer blood retina barrier containing RPE and three dimensional (3D) vascularized tissue has been produced using bioprinting techniques with human induced pluripotent stem cells. It successfully recapitulates features of choriocapillaris and components of Bruchs membranes including RPE induced vascular endothelial fenestration and extracellular matrix formation. We have further demonstrated that HIF-1 induced angiogenesis towards RPE in the tissue and the reduction of the induced angiogenesis with improved barrier functions by bevacizumab treatment. We have also explored the usefulness of this 3D retina tissue model to investigate Zika virus infection and demonstrated viral infection in the tissue and disruption of barrier function. This 3D vascularized ocular tissue model therefore provides extensive opportunities to study underlying mechanisms of relevant diseases and the development of therapeutics.
利用生物打印技术,利用人诱导多能干细胞制备了含RPE和三维血管化组织的体外血视网膜屏障眼组织。它成功地概括了绒毛膜的特征和布鲁氏膜的成分,包括RPE诱导的血管内皮开窗和细胞外基质的形成。我们进一步证明了HIF-1诱导了组织中RPE的血管生成,贝伐单抗治疗减少了诱导的血管生成,改善了屏障功能。我们还探索了这种3D视网膜组织模型在研究寨卡病毒感染方面的有用性,并证明了病毒在组织中的感染和屏障功能的破坏。因此,这种三维血管化眼组织模型为研究相关疾病的潜在机制和治疗方法的发展提供了广泛的机会。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A platform of assays for the discovery of anti-Zika small-molecules with activity in a 3D-bioprinted outer-blood-retina model.
- DOI:10.1371/journal.pone.0261821
- 发表时间:2022
- 期刊:
- 影响因子:3.7
- 作者:Dorjsuren D;Eastman RT;Song MJ;Yasgar A;Chen Y;Bharti K;Zakharov AV;Jadhav A;Ferrer M;Shi PY;Simeonov A
- 通讯作者:Simeonov A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc Ferrer其他文献
Marc Ferrer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc Ferrer', 18)}}的其他基金
Identification of novel agonist of the Relaxin family peptide receptor 2 (RXFP2) as potential new therapeutics for testicular maldescent
鉴定松弛素家族肽受体 2 (RXFP2) 的新型激动剂作为睾丸衰退的潜在新疗法
- 批准号:
9205645 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
3D Bioprinted Omentum tissue to model ovarian cancer metastasis
3D 生物打印网膜组织用于模拟卵巢癌转移
- 批准号:
10683668 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
3D Bioprinted lung cancer models for drug screening
用于药物筛选的 3D 生物打印肺癌模型
- 批准号:
10907367 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
Targeting Tumor-derived exRNA-Containing microvesicles by high throughput screening
通过高通量筛选靶向肿瘤来源的含有 exRNA 的微泡
- 批准号:
9359917 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
Identification of Small Molecule Effectors that target the Fungal-Specific Kinase Drk1 as Novel Antifungal Drug Leads
鉴定靶向真菌特异性激酶 Drk1 作为新型抗真菌药物先导物的小分子效应器
- 批准号:
9205652 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
3D Bioprinting of human native-like tissues as disease-in-a-dish models for drug discovery
人类天然组织的 3D 生物打印作为药物发现的皿中疾病模型
- 批准号:
9355001 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
PAC1 receptor antagonists as potential treatments for depression and atherosclerosis associated with chronic stress
PAC1 受体拮抗剂作为慢性应激相关抑郁症和动脉粥样硬化的潜在治疗方法
- 批准号:
9360500 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
Small molecule inhibitor screen of MHC II processing pathways using influenza virus A/PR/8/34
使用流感病毒 A/PR/8/34 筛选 MHC II 加工途径的小分子抑制剂
- 批准号:
9205649 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
Identification of Small Molecule Inhibitors of PHF5A for Glioblastoma
胶质母细胞瘤 PHF5A 小分子抑制剂的鉴定
- 批准号:
9360504 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
Identification of small molecule inhibitors of miR-155 expression in Th17 cells
Th17细胞中miR-155表达的小分子抑制剂的鉴定
- 批准号:
9205636 - 财政年份:
- 资助金额:
$ 226.91万 - 项目类别:
相似海外基金
Transport mechanisms of cell-penetrating peptides at the blood-retinal barrier to establish strategies of macromolecular drug delivery
细胞穿透肽在血视网膜屏障上的转运机制,以建立大分子药物递送策略
- 批准号:
22H02780 - 财政年份:2022
- 资助金额:
$ 226.91万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Collaborative Research: Modular, vascularized microphysiological systems to study the outer blood retinal barrier
合作研究:模块化、血管化的微生理系统研究外血视网膜屏障
- 批准号:
2225438 - 财政年份:2022
- 资助金额:
$ 226.91万 - 项目类别:
Standard Grant
Collaborative Research: Modular, vascularized microphysiological systems to study the outer blood retinal barrier
合作研究:模块化、血管化的微生理系统研究外血视网膜屏障
- 批准号:
2308628 - 财政年份:2022
- 资助金额:
$ 226.91万 - 项目类别:
Standard Grant
Microglia-Vascular Interaction in Alteration of Blood-Retinal Barrier in Diabetic Retinopathy
小胶质细胞-血管相互作用在糖尿病视网膜病变血-视网膜屏障改变中的作用
- 批准号:
10512065 - 财政年份:2021
- 资助金额:
$ 226.91万 - 项目类别:
Microglia-Vascular Interaction in Alteration of Blood-Retinal Barrier in Diabetic Retinopathy
小胶质细胞-血管相互作用在糖尿病视网膜病变血-视网膜屏障改变中的作用
- 批准号:
10258513 - 财政年份:2021
- 资助金额:
$ 226.91万 - 项目类别:
Role of MCT9 and 14 as mechanisms of transporting cationic drugs/compounds at the blood-retinal barrier.
MCT9 和 14 作为在血-视网膜屏障转运阳离子药物/化合物的机制的作用。
- 批准号:
20H03403 - 财政年份:2020
- 资助金额:
$ 226.91万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Establishing ex vivo methods to elucidate efflux transport of drugs at the blood-retinal barrier for retinal drug development
建立离体方法来阐明药物在血-视网膜屏障处的外排转运,用于视网膜药物开发
- 批准号:
19K07160 - 财政年份:2019
- 资助金额:
$ 226.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cellular and molecular mechanisms of retinoic acid-mediated blood-retinal barrier regulation
视黄酸介导的血视网膜屏障调节的细胞和分子机制
- 批准号:
9760685 - 财政年份:2019
- 资助金额:
$ 226.91万 - 项目类别:
Analysis of blood-retinal barrier based on circadian expression of drug transporters.
基于药物转运蛋白昼夜节律表达的血视网膜屏障分析。
- 批准号:
17H06976 - 财政年份:2017
- 资助金额:
$ 226.91万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Regulation of blood-retinal barrier by placental growth factor.
胎盘生长因子对血视网膜屏障的调节。
- 批准号:
9290552 - 财政年份:2017
- 资助金额:
$ 226.91万 - 项目类别:














{{item.name}}会员




